Table 2.
Beta interferons and glatiramer acetate for subcutaneous administration in multiple sclerosis [64, 65]
| Molecule | Brand name (originator) | Dosing frequency | Injection volume | Device |
|---|---|---|---|---|
| Interferon | ||||
| Interferon beta-1b | Betaseron/Betaferon (Bayer) | q2d | 0.25–1 ml | Prefilled syringea, vial, autoinjector |
| Extavia (Novartis) | q2d | 0.25–1 ml | Prefilled syringea, vial, autoinjector | |
| Peg-interferon beta-1a | Plegridy (Biogen) | q2w | 0.5 ml | Prefilled syringe, prefilled pen/autoinjector |
| Interferon beta-1a | Rebif (EMD Serono/Pfizer) | Three times per week | 0.2–0.5 ml | Prefilled syringe, prefilled pen/autoinjector, electronic injection system |
| Glatiramer acetate | ||||
| Glatiramer acetate | Copaxone (Teva) | q1d or three times per week | 1 ml | Prefilled syringe, pen/autoinjector |
qXd once every X days, qXw once every X weeks
aPrefilled diluent syringe with vial